Open AccessLipid and carbohydrate effects of a new triphasic oral contraceptive containing norgestimate
Author(s) -
Burkman Ronald T.,
Kafrissen Michael Edwin,
Olson William,
Osterman Jennifer
Publication year - 1992
Publication title -
acta obstetricia et gynecologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.401
H-Index - 102
eISSN - 1600-0412
pISSN - 0001-6349
DOI - 10.3109/00016349209156508
Subject(s) - medicine , endocrinology , ethinylestradiol , hemoglobin , cholesterol , carbohydrate , gestodene , insulin , population , research methodology , family planning , environmental health
Data arc reported from the combined results of two studies assessing the lipid and carbohydrate effects of a triphasic preparation of norgestimate and ethinyl estradiol (Ortho TriCyclen®, Tri‐Cilest®) over a 2‐year period in 1,783 healthy women. Mean values for serum levels of high‐density lipoprotein cholesterol (HDL‐C) were increased significantly. with a percent change at 24 months of 13.2. Values for the ratio of low‐density lipoprotein cholesterol to HDL‐C were reduced throughout the study period (mean change of −6.4%, at cycle 24). There were no clinically significant changes in fasting blood glucose levels or insulin levels or in values for glycosylated hemoglobin. These results are consistent with those of previous studies and indicate that the triphasic preparation of norgestimate and ethinyl estradiol is a selective and minimally androgenic oral contraceptive agent. Long‐term therapeutic benefit may accrue from the favorable influences on the lipid profile.